Published in Diabetes Metab Syndr Obes on October 04, 2017
The disease burden associated with overweight and obesity. JAMA (1999) 19.39
Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA (2013) 18.86
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med (2015) 11.05
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ (2007) 9.10
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (2009) 7.24
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med (2010) 6.63
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (1998) 6.17
Long-term maintenance of weight loss: current status. Health Psychol (2000) 6.03
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2010) 4.23
Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med (2005) 4.04
Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ (2007) 3.99
Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) (2005) 3.42
A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord (1997) 3.05
Obesity as a major risk factor for cancer. J Obes (2013) 2.26
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) (2010) 2.25
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther (2008) 2.17
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) (2011) 2.08
Central control of body weight and appetite. J Clin Endocrinol Metab (2008) 1.91
Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) (2002) 1.76
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) (2012) 1.66
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA (2015) 1.56
Current and predicted prevalence of obesity in Canada: a trend analysis. CMAJ Open (2014) 1.41
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) (2013) 1.39
Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord (2003) 1.38
Anti-obesity drugs: past, present and future. Dis Model Mech (2012) 1.36
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov (2012) 1.29
Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev (2009) 1.10
National survey of US primary care physicians' perspectives about causes of obesity and solutions to improve care. BMJ Open (2012) 1.07
Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta-analysis of direct comparisons. J Acad Nutr Diet (2014) 1.05
Obesity and appetite control. Exp Diabetes Res (2012) 1.05
Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab (2014) 1.04
Orlistat. Drugs (1998) 0.99
Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery. Diabetologia (2014) 0.87
Mechanisms responsible for excess weight loss after bariatric surgery. J Diabetes Sci Technol (2011) 0.84
Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults. P T (2011) 0.80
Interest, views and perceived barriers to bariatric surgery in patients with morbid obesity. Clin Obes (2016) 0.80
Receptivity to Bariatric Surgery in Qualified Patients. J Obes (2016) 0.79
Consequences of Weight Cycling: An Increase in Disease Risk? Int J Exerc Sci (2009) 0.77
Long-Term Outcomes of Roux-en-Y Gastric Bypass Conversion of Failed Laparoscopic Gastric Band. Obes Surg (2017) 0.76
Physiology of weight loss surgery. Surg Clin North Am (2011) 0.75